Richard Pratley
AdventHealth · AdventHealth Orlando · Study Principal Investigator
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Richard Pratley as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07421518 · Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 InhibitorsAdventHealth Translational Research Institute · not yet recruiting · Type 1 Diabetes, Type 2 Diabetes · principal investigator
- N/ANCT04805970 · REsearching Covid-19 Outcomes in Diabetes (RECODE)AdventHealth Translational Research Institute · active not recruiting · Covid19, Diabetes · principal investigator
- Ph2NCT04432090 · GPR119 Agonist for Hypoglycemia in Type 1 DiabetesAdventHealth Translational Research Institute · completed · Diabetes Mellitus, Type 1 · principal investigator
- N/ANCT04164966 · Development of Novel Biomarkers for the Early Diagnosis of Type 1 DiabetesAdventHealth Translational Research Institute · active not recruiting · Type 1 Diabetes · principal investigator
- N/ANCT03651622 · ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)University of North Carolina, Chapel Hill · completed · Diabetes Mellitus, Type 1, Overweight and Obesity · principal investigator
- N/ANCT03379792 · The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 DiabetesAdventHealth Translational Research Institute · completed · Type 1 Diabetes · principal investigator
- Ph1NCT03234751 · Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant SubjectsAdventHealth Translational Research Institute · completed · Diabetes · principal investigator
- N/ANCT03032640 · Interactions of Human Gut Microbiota With Intestinal Sweet Taste ReceptorsAdventHealth Translational Research Institute · completed · Obesity · principal investigator
- N/ANCT02859116 · Collection of Gastrointestinal Tissue Samples for the Characterization and ex Vivo Functional Assessment of ChemoreceptorsAdventHealth Translational Research Institute · completed · Diabetes · principal investigator
- N/ANCT02531607 · Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)AdventHealth · active not recruiting · Pancreatic Neoplasms · principal investigator
- N/ANCT02459106 · Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in HumansAdventHealth Translational Research Institute · completed · Type 2 Diabetes Mellitus · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 8 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Advanced Insulin Delivery to Reduce Impaired Awareness of Hypoglycemia in a T1D Cohort (AIDRIAHT1C)U01DK135131 · NIDDK · ADVENTHEALTH ORLANDO · fiscal years 2022 to 2026 · $740,881 awarded in 2026Same name and institution; not confirmed by an ID
- Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium – UF Health and AdventHealth Combined Clinical CenterU01DK127392 · NIDDK · UNIVERSITY OF FLORIDA · fiscal years 2020 to 2026 · $480,000 awarded in 2026Same name and institution; not confirmed by an ID
- The Chronic Pancreatitis Clinical Research ConsortiumU01DK144420 · NIDDK · UNIVERSITY OF FLORIDA · fiscal years 2025 to 2026 · $404,327 awarded in 2026Same name and institution; not confirmed by an ID
- Ketone Monitoring Approaches for DKA Risk Mitigation in People with T1D on Adjunctive SGLT2 Inhibitors (KARMA)U01DK143384 · NIDDK · ADVENTHEALTH ORLANDO · fiscal years 2025 · $2,477,577 awarded in 2025Same name and institution; not confirmed by an ID
- Accelerating Solutions to Optimize Glycemic Control and Weight Management In Young Adults with Type 1 DiabetesDP3DK113358 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2017 · $1,911,815 awarded in 2017Grant number is on one of their registry trials
- Cross-sectional and Longitudinal Study of "pre-diabetes" in the Pima IndiansZ01DK069015 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · fiscal years 1998 to 2000Same name and institution; not confirmed by an ID
- Insulin Secretory Defects in Pima Indians at High Risk for NIDDMZ01DK069068 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · fiscal years 1998 to 2000Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:40 UTC. The ranking covers the 200 most relevant of 134 PubMed records, and a shared surname and initials can bring in a namesake. All 134 on PubMed
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.N Engl J Med · 20241,618 citationsRCR 281.5
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.N Engl J Med · 20201,184 citationsRCR 61.7
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.N Engl J Med · 2021707 citationsRCR 44.8
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.Lancet Diabetes Endocrinol · 2018646 citationsRCR 27.1
- Vitamin D Supplementation and Prevention of Type 2 Diabetes.N Engl J Med · 2019486 citationsRCR 25.9
- 469 citationsRCR 13.4
- 457 citationsRCR 20.8
- Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.N Engl J Med · 2017401 citationsRCR 15.6
- 299 citationsRCR 16.1
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.Lancet Diabetes Endocrinol · 2019294 citationsRCR 13.3